Loading...
Compared with bare metal stents (and balloon angioplasty), drug-eluting stents (DES) have markedly improved the outcomes of percutaneous coronary intervention (PCI), mainly through reductions in restenosis due to neointimal hyperplasia, generally seen during the first year after PCI. However, current-generation DES experience late failure at approximately 2% annually through 5 years and probably indefinitely, likely caused (partly at least) by ongoing vascular injury from the metallic implant. Swedish investigators have now performed an industry-funded, randomized trial comparing a novel drug-eluting scaffold, the DynamX bioadaptor, with a current-generation DES in 2399 patients (median age, 70; 24% women) undergoing PCI for stable or unsta…